Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
PaperCitations, authors & open-access status
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 17 citations, 2023 year and closed oa status.
17
Citations
2023
Year
closed
OA Status